Wide Ranks

JNJ

Johnson & Johnson

155.40

Top Statistics
Market Cap 374 B Forward PE 14.62 Revenue Growth 5.20 %
Current Ratio 1.03 Trailing PE 25.69 Earnings Growth -89.10 %
Profit Margins 16.74 % Peg Ratio Dividend Yield 3.19 %
Enterprice / EBITA 12.96 Enterprise / Revenue 4.44 Price To Sales Trailing12 Months 4.27
Profitability
Profit Margins 16.74 % Operating Margins 24.52 %
Balance Sheet
Total Cash 20 B Total Cash Per Share 8.43 Total Debt 35 B
Total Debt To Equity 50.96 Current Ratio 1.03 Book Value Per Share 29.14
All Measures
Short Ratio 254.00 % Message Board Id finmb_139677 Shares Short Prior Month 18 M
Return On Equity 0.2089 City New Brunswick Uuid 73aa25b0-87c8-3616-a460-03cbef1b4753
Previous Close 154.52 First Trade Date Epoch Utc -252322200 Book Value 29.14
Beta 0.5180 Total Debt 35 B Volume 4 M
Price To Book 5.33 Last Split Date 992 M Fifty Two Week Low 143.13
Total Cash Per Share 8.43 Total Revenue 87 B Shares Short Previous Month Date 1 B
Target Median Price 175.00 Max Age 86400 Recommendation Mean 2.21
Sand P52 Week Change 0.3133 Operating Margins 24.52 % Last Dividend Value 1.24
Target Mean Price 174.89 Net Income To Common 14 B Ask 155.33
Short Percent Of Float 0.0073 Implied Shares Outstanding 2 B Last Fiscal Year End 1 B
Trailing Peg Ratio 92.55 % Average Daily Volume10 Day 8 M Average Volume10days 8 M
Total Cash 20 B Next Fiscal Year End 1 B Revenue Per Share 36.43
Held Percent Insiders 0.0009 Ebitda Margins 34.27 % Dividend Rate 4.96
Trailing PE 25.69 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 154.52 Target Low Price 155.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 159.51 Open 154.63 Dividend Yield 3.19 %
State NJ Free Cashflow 19 B Return On Assets 0.0840
Time Zone Short Name EST Trailing Eps 6.05 Day Low 154.60
Address1 One Johnson & Johnson Plaza Trailing Annual Dividend Rate 4.86 Price Hint 2
Shares Outstanding 2 B Target High Price 215.00 Website https://www.jnj.com
52 Week Change 0.0048 Average Volume 6 M Earnings Quarterly Growth -89.70 %
Forward Eps 10.60 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 70.50 % Last Split Factor 2:1 Regular Market Day High 156.62
Is_sp_500 True Profit Margins 16.74 % Debt To Equity 50.96
Fifty Two Week High 168.85 Day High 156.62 Shares Short 17 M
Regular Market Open 154.63 Industry Key drug-manufacturers-general Bid 155.33
Earnings Growth -89.10 % Enterprise To Revenue 4.44 Revenue Growth 5.20 %
Shares Percent Shares Out 0.0073 Operating Cashflow 25 B Five Year Avg Dividend Yield 271.00 %
Currency USD Market Cap 374 B Time Zone Full Name America/New_York
Is_nasdaq_100 False Zip 08933 Payout Ratio 80.33 %
Quote Type EQUITY Industry Drug Manufacturers - General Ex Dividend Date 1 B
Regular Market Day Low 154.60 Held Percent Institutions 0.7312 Long Name Johnson & Johnson
Current Price 155.40 Enterprise To Ebitda 12.96 Financial Currency USD
Trailing Annual Dividend Yield 3.15 % Current Ratio 1.03 Gross Margins 69.39 %
Industry Disp Drug Manufacturers - General Number Of Analyst Opinions 23 Country United States
Float Shares 2 B Two Hundred Day Average 155.82 Ir Website http://www.investor.jnj.com/investor-relations.cfm
Enterprise Value 389 B Price To Sales Trailing12 Months 4.27 Forward PE 14.62
Regular Market Volume 4 M Last Dividend Date 1 B Ebitda 30 B
Exchange NYQ
Go to Yahoo Finance Go to Seeking Alpha 
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide.

The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke.

this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery.

It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics.

The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis.

Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.